Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dolutegravir + emtricitabine + tenofovir disoproxil fumarate
- Development stage
- Phase 4
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It combines dolutegravir (an integrase strand transfer inhibitor) with emtricitabine and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors). This combination provides a complete antiretroviral regimen in a single tablet, supporting adherence to HIV treatment.
- Other names
- DTG/FTC/TDF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseIntegrase allosteric pocket (HIV)
Beyond the preview
Go deeper on dolutegravir + emtricitabine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dolutegravir + emtricitabine + tenofovir disoproxil fumarate.